Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors

A legfontosabb adatok

Ki végzi
Wroclaw Medical University
Hol
Lengyelország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
300 fő, tervezett
Kezdés
2025. júl. 1.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • Treatment with SGLT2 inhibitors (flozins)
A regiszteradat frissítve
2026. március 23.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with peripheral arterial disease who had a procedure to restore blood flow in the legs. It compares people who took SGLT2 inhibitors (flozins) after the procedure with people who did not.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
Peripheral arterial disease with acute or chronic poor blood flow (ischemia), treated with open surgery or a minimally invasive procedure on the leg arteries.
Korábbi kezelés
In the flozin group: SGLT2 inhibitors taken for at least 3 months before the procedure, or started right after it, for any reason. The other group did not take flozins in the year after the procedure.

A részvétel fő kizáró okai

  • Procedure done because of an injury to a blood vessel
  • Amputation for reasons other than poor blood flow, such as cancer, nerve damage or injury
  • Another planned procedure to restore blood flow outside the legs at hospital discharge, such as heart or neck arteries
  • Planned amputation or repeat surgery on the treated leg at hospital discharge
  • Another planned major surgery with high heart and blood vessel risk at hospital discharge

A regiszter feltételei, szó szerint

Mind a 8 feltétel megnézéseKevesebb

Ki vehet részt

  • Peripheral vascular procedure ( Conventional surgical procedure or minimally invasive procedure) due to acute or chronic ischemia
  • Use of SGLT2 inhibitors (applies only to the group exposed to flozins) for at least 3 months prior to the vascular procedure (the indication for initiating the drug is irrelevant: chronic kidney disease [CKD] / cardiac reasons / diabetes), or immediately after the vascular procedure
  • Ability to determine the patient's outcomes within a minimum of 30 days up to 1 year following the vascular procedure

Ki nem vehet részt

  • Planned other major surgical procedure with high cardiovascular risk at the time of hospital discharge
  • Amputation due to causes other than ischemia (e.g., cancer, neuropathy, trauma without coexisting ischemia)
  • Vascular injury as the reason for the procedure
  • Planned revascularization procedure other than for the lower limbs at the time of hospital discharge (e.g., coronary or carotid arteries)
  • Planned ischemia-related amputation or reoperation of the operated limb at the time of hospital discharge

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The study is observational and involves patients (pts) with peripheral arterial occlusive disease (PAD) who have undergone lower limb revascularization procedures. Patients who are at least one year post-procedure will be contacted by phone and asked whether any cardiovascular complications occurred during that period, specifically major adverse cardiovascular events (MACE) or major adverse limb events (MALE), and whether they had been taking sodium-glucose co-transporter 2 inhibitors (SGLT2-i, "flozins") during the year following the procedure. The results from the group of pts who, for any reason, received SGLT2-i treatment after the vascular procedure (including those who had initiated treatment before surgery) will be compared to the results from the group of patients who did not receive such treatment, with regard to the occurrence of the aforementioned complications.

A vizsgálat 2 csoportja

  • Patients after vascular surgery treated with flozins

    Patients aged ≥18 years who have undergone vascular surgery (either open or minimally invasive procedures) and, for any reason, were treated with SGLT2 inhibitors ("flozins") during the one-year follow-up period after the procedure.

    Kezelés: Treatment with SGLT2 inhibitors (flozins)

  • Patients after vascular surgery with no exposure to flozins (controls)

    Patients aged ≥18 years who have undergone vascular surgery (either open or minimally invasive procedures) and were not exposed to SGLT2 inhibitors ("flozins") during the one-year follow-up period after the procedure.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Ocena powikłań Naczyniowych u pacjentów Poddanych Rewaskularyzacji Obwodowej: wpływ inhibitorów SGLT-2 The Assessment of Vascular Complications in Patients Undergoing Peripheral Revascularization: The Impact of SGLT-2 Inhibitors
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. március 23.